-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Ginkgo Bioworks (NYSE:DNA) Shares Gap Up to $3.17
Ginkgo Bioworks (NYSE:DNA) Shares Gap Up to $3.17
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating)'s share price gapped up before the market opened on Tuesday . The stock had previously closed at $3.17, but opened at $3.28. Ginkgo Bioworks shares last traded at $3.24, with a volume of 339,500 shares.
Analysts Set New Price Targets
A number of research firms have issued reports on DNA. Raymond James increased their target price on shares of Ginkgo Bioworks from $11.50 to $14.50 and gave the stock an "outperform" rating in a report on Tuesday, August 16th. Bank of America lowered shares of Ginkgo Bioworks from a "neutral" rating to an "underperform" rating and set a $3.00 target price on the stock. in a report on Wednesday, May 18th. BTIG Research increased their target price on shares of Ginkgo Bioworks from $5.00 to $6.00 and gave the stock a "buy" rating in a report on Tuesday, August 16th. Finally, Jefferies Financial Group dropped their price objective on shares of Ginkgo Bioworks from $11.50 to $4.35 in a research report on Thursday, June 16th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Ginkgo Bioworks presently has a consensus rating of "Moderate Buy" and an average target price of $8.69.
Get Ginkgo Bioworks alerts:Ginkgo Bioworks Price Performance
The company has a debt-to-equity ratio of 0.03, a quick ratio of 11.78 and a current ratio of 11.84. The company has a market capitalization of $5.48 billion, a PE ratio of -1.57 and a beta of 1.84. The company's 50-day simple moving average is $2.98 and its 200-day simple moving average is $3.10.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Lincoln National Corp acquired a new stake in shares of Ginkgo Bioworks in the 2nd quarter worth $26,000. Atria Wealth Solutions Inc. acquired a new stake in shares of Ginkgo Bioworks in the 2nd quarter worth $30,000. Cetera Investment Advisers acquired a new stake in shares of Ginkgo Bioworks in the 2nd quarter worth $33,000. First Horizon Advisors Inc. acquired a new stake in shares of Ginkgo Bioworks in the 2nd quarter worth $38,000. Finally, Endurance Wealth Management Inc. lifted its stake in shares of Ginkgo Bioworks by 100.0% in the 1st quarter. Endurance Wealth Management Inc. now owns 10,000 shares of the company's stock worth $40,000 after acquiring an additional 5,000 shares during the period. 53.37% of the stock is owned by hedge funds and other institutional investors.About Ginkgo Bioworks
(Get Rating)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
Featured Stories
- Get a free copy of the StockNews.com research report on Ginkgo Bioworks (DNA)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Four Cheap Stocks With Interesting Insider Activity
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating)'s share price gapped up before the market opened on Tuesday . The stock had previously closed at $3.17, but opened at $3.28. Ginkgo Bioworks shares last traded at $3.24, with a volume of 339,500 shares.
Ginkgo Bioworks Holdings，Inc.(纽约证券交易所代码：DNA-GET Rating)的股价在周二开盘前大幅上涨。该股之前的收盘价为3.17美元，但开盘时为3.28美元。银杏生物控股公司的股票最后交易价格为3.24美元，成交量为33.95万股。
Analysts Set New Price Targets
分析师设定新的价格目标
A number of research firms have issued reports on DNA. Raymond James increased their target price on shares of Ginkgo Bioworks from $11.50 to $14.50 and gave the stock an "outperform" rating in a report on Tuesday, August 16th. Bank of America lowered shares of Ginkgo Bioworks from a "neutral" rating to an "underperform" rating and set a $3.00 target price on the stock. in a report on Wednesday, May 18th. BTIG Research increased their target price on shares of Ginkgo Bioworks from $5.00 to $6.00 and gave the stock a "buy" rating in a report on Tuesday, August 16th. Finally, Jefferies Financial Group dropped their price objective on shares of Ginkgo Bioworks from $11.50 to $4.35 in a research report on Thursday, June 16th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Ginkgo Bioworks presently has a consensus rating of "Moderate Buy" and an average target price of $8.69.
一些研究公司已经发布了关于DNA的报告。雷蒙德·詹姆斯在8月16日(星期二)的一份报告中将银杏生物工场的股票目标价从11.50美元上调至14.50美元，并给予该股“跑赢大盘”的评级。美国银行将Ginkgo Bioworks的股票评级从中性下调至表现不佳，并为该股设定了3.00美元的目标价。在5月18日星期三的一份报告中。BTIG Research在8月16日(星期二)的一份报告中将银杏生物工场股票的目标价从5.00美元上调至6.00美元，并给予该股“买入”评级。最后，杰富瑞金融集团在6月16日星期四的一份研究报告中将银杏生物的股票目标价从11.50美元下调至4.35美元。一位研究分析师对该股的评级为卖出，一位分析师给出了持有评级，六位分析师给出了该公司的买入评级。根据MarketBeat.com的数据，银杏生物目前的共识评级为“中等买入”，平均目标价为8.69美元。
Ginkgo Bioworks Price Performance
银杏生物工场性价比
The company has a debt-to-equity ratio of 0.03, a quick ratio of 11.78 and a current ratio of 11.84. The company has a market capitalization of $5.48 billion, a PE ratio of -1.57 and a beta of 1.84. The company's 50-day simple moving average is $2.98 and its 200-day simple moving average is $3.10.
该公司的负债权益比率为0.03，速动比率为11.78，流动比率为11.84。该公司市值为54.8亿美元，市盈率为-1.57，贝塔系数为1.84。该公司的50日简单移动均线切入位在2.98美元，200日简单移动均线切入位在3.10美元。
Institutional Inflows and Outflows
机构资金流入和流出
About Ginkgo Bioworks
关于银杏生物工场
(Get Rating)
(获取评级)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
银杏生物工程控股公司及其子公司开发细胞编程平台。它的平台用于对细胞进行编程，以实现产品的生物生产，如新型疗法、食品配料和从石油中提取的化学品。该公司服务于各种终端市场，包括特种化学品、农业、食品、消费品和药品。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Ginkgo Bioworks (DNA)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Four Cheap Stocks With Interesting Insider Activity
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
- 免费获取StockNews.com关于银杏生物工程(DNA)的研究报告
- 这家医疗设备制造商准备好继续反弹了吗？
- 第三季度财报公布前最值得关注的五(5)只股票
- Take-Two Interactive是否已经退化为一招小马？
- 具有有趣内幕活动的四只廉价股票
- 健康饮料制造商Celsius能否超越其Monster竞争对手？
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
接受《银杏生物工场日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对银杏生物工程和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧